Predictive factors for response and progression after treatment with rituximab in previously untreated patients with Waldenstrom's macroglobulinemia (WM).

被引：0
|
作者：
Anagnostopoulos, A
Treon, SP
Zervas, K
Branagan, A
Gika, D
Zomas, A
Kyrtsonis, MC
Vassou, A
Anagnostopoulos, N
Pangalis, G
Dimopoulos, MA
机构：
[1] Greek Myeloma Study Grp, Dept Clin Therapeut, Athens, Greece
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3485
引用
收藏
页码：973A / 973A
页数：1
相关论文
共 50 条
  • [1] Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression
    Dimopoulos, MA
    Alexanian, R
    Gika, D
    Anagnostopoulos, A
    Zervas, C
    Zomas, A
    Kyrtsonis, MC
    Anagnostopoulos, N
    Pangalis, GA
    Weber, DM
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2057 - 2061
  • [2] Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia
    Dimopoulos, MA
    Anagnostopoulos, A
    Zervas, C
    Kyrtsonis, MC
    Zomas, A
    Bourantas, C
    Anagnostopoulos, N
    Pangalis, G
    CLINICAL LYMPHOMA, 2005, 5 (04): : 270 - 272
  • [3] Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia
    Dimopoulos, MA
    Zervas, C
    Zomas, A
    Hamilos, G
    Gika, D
    Efstathiou, E
    Panayiotidis, P
    Vervessou, E
    Anagnostopoulos, N
    Christakis, J
    CLINICAL LYMPHOMA, 2002, 3 (03): : 163 - 166
  • [4] Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrom Macroglobulinemia
    Castillo, Jorge J.
    Gustine, Joshua
    Meid, Kirsten
    Dubeau, Toni
    Yang, Guang
    Xu, Lian
    Hunter, Zachary
    Treon, Steven P.
    BLOOD, 2016, 128 (22)
  • [5] Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression.
    Dimopoulos, MA
    Zervas, K
    Zomas, A
    Anagnostopoulos, A
    Kyrtsonis, MC
    Anagnostopoulos, N
    Pangalis, G
    Weber, D
    BLOOD, 2003, 102 (11) : 448A - 448A
  • [6] Impact of Rituximab On the Treatment of Waldenstrom's Macroglobulinemia (WM)
    Thomas, Sheeba K.
    Delasalle, Kay B.
    Shah, Jatin J.
    Wang, Luhua
    Orlowski, Robert Z.
    Weber, Donna M.
    BLOOD, 2012, 120 (21)
  • [7] Primary treatment of Waldenstrom's macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide.
    Dimopoulos, Meletios A.
    Anagnostopoulos, Athanasios
    Kyrtsonis, Marie Christine
    Tsatalas, Constantinos
    Kokkini, Garyfallia
    Repoussis, Panagiotis
    Zomas, Athanasios
    Symeonidis, Argiris
    Michali, Evridiki
    Anagnostopoulos, Nikolaos
    Terpos, Evangelos
    Economopoulos, Theophanis
    Pangalis, Gerasimos
    BLOOD, 2006, 108 (11) : 42A - 42A
  • [8] Primary treatment of Waldenstrom's Macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide.
    Dimopoulos, MA
    Kyrtsonis, MC
    Tsatalas, C
    Kokkini, G
    Repoussis, P
    Zomas, A
    Symeonidis, A
    Michali, E
    Anagnostopoulos, A
    Anagnostopoulos, N
    Economopoulos, T
    Pangalis, G
    BLOOD, 2004, 104 (11) : 215A - 215A
  • [9] Rituximab for Waldenstrom's macroglobulinemia (WM) (E3A98): An ECOG phase II pilot study for untreated or previously treated patients.
    Gertz, MA
    Rue, M
    Blood, E
    Kaminer, LS
    Vesole, DH
    Greipp, PR
    BLOOD, 2003, 102 (11) : 148A - 148A
  • [10] BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM)
    Improta, S.
    Villa, M.
    Gagliardi, A.
    Lucania, A.
    Della Cioppa, P.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2013, 98 : 638 - 638
12345